Atea Pharmaceuticals, whose stock is traded as AVIR, has been the subject of various reports and analyses. Some outlets are discussing the company's stock price and forecast, while others are reporting on developments such as option grants and potential catalysts. Additionally, there are investigations and alerts related to the company, but the nature and outcome of these are unclear.